Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | BTN3A1 | O00481 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MVD | P53602 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyl Alcohol SCHEMBL10862392 | 0.78 | FDPS (0.39) | FDPSBLMTDP1BTN3A1MVD | |
| Triphosphate SCHEMBL28345672 | 0.77 | FDPS (0.56) | FDPSBLMTDP1BTN3A1MVD | |
| SCHEMBL8336437 | 0.77 | FDPS (0.39) | FDPSBLMTDP1KDM4ECYP2C19 | |
| SCHEMBL2871051 | 0.74 | FDPS (0.45) | FDPSBLMTDP1BTN3A1MVD | |
| Triphosphate SCHEMBL18714 | 0.73 | FDPS (0.69) | FDPSBLMTDP1BTN3A1MVD | |
| Triphosphate SCHEMBL15555988 | 0.73 | FDPS (0.69) | FDPSBLMTDP1BTN3A1MVD | |
| Triphosphate SCHEMBL25284822 | 0.70 | FDPS (0.64) | FDPSBLMTDP1BTN3A1MVD | |
| Triphosphate SCHEMBL11327149 | 0.70 | FDPS (0.64) | FDPSBLMTDP1BTN3A1MVD | |
| SCHEMBL897837 | 0.70 | FDPS (0.64) | FDPSBLMTDP1BTN3A1MVD | |
| Triphosphate SCHEMBL22717549 | 0.70 | FDPS (0.64) | FDPSBLMTDP1BTN3A1MVD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3705485-B1 | METHOD FOR PREPARING CANGRELOR TETRASODIUM SALT | YABAO PHARMACEUTICAL GROUP CO LTD (CN) | 2023-11-01 | — | — | EP | claimed |
| CN-110913911-A | Combination therapy for the treatment of cancer | 特沙诺有限公司 | 2020-03-24 | — | — | CN | claimed |
| EP-3705485-B1 | METHOD FOR PREPARING CANGRELOR TETRASODIUM SALT | YABAO PHARMACEUTICAL GROUP CO LTD (CN) | 2023-11-01 | — | — | EP | disclosed |
| US-11440934-B2 | Method for preparing cangrelor tetrasodium salt | YABAO PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-09-13 | — | — | US | disclosed |
| CN-108658989-B | Preparation method and application of cangrelor intermediate | 一禾(湖州)生物医药科技有限公司 | 2022-04-08 | — | — | CN | disclosed |
| CN-112898347-A | Preparation method of cangrelor key intermediate | 北京阳光诺和药物研究股份有限公司 | 2021-06-04 | — | — | CN | disclosed |
| CN-110913911-A | Combination therapy for the treatment of cancer | 特沙诺有限公司 | 2020-03-24 | — | — | CN | disclosed |
| US-20100093873-A1 | Methods of improving therapy of perfluorocarbons (PFC) | GOLDFISCHER SIDNEY L | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11440934-B2 | Method for preparing cangrelor tetrasodium salt | ADORA2A, SRM, P2RY4 | FDPS 1527/4885BLM 2243/4885TDP1 2729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.